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Abstract
Introduction: Chronic traumatic encephalopathy (CTE) is a progressive neurodegeneration associated with
repetitive head impacts. Understanding Neurologic Injury and Traumatic Encephalopathy (UNITE) is a U01 project
recently funded by the National Institute of Neurological Disorders and Stroke and the National Institute of
Biomedical Imaging and Bioengineering. The goal of the UNITE project is to examine the neuropathology and
clinical presentation of brain donors designated as “at risk” for the development of CTE based on prior athletic or
military exposure. Here, we present the rationale and methodology for UNITE.
Methods: Over the course of 4 years, we will analyze the brains and spinal cords of 300 deceased subjects who
had a history of repetitive head impacts sustained during participation in contact sports at the professional or
collegiate level or during military service. Clinical data are collected through medical record review and retrospective
structured and unstructured family interviews conducted by a behavioral neurologist or neuropsychologist. Blinded to
the clinical data, a neuropathologist conducts a comprehensive assessment for neurodegenerative disease, including
CTE, using published criteria. At a clinicopathological conference, a panel of physicians and neuropsychologists, blinded
to the neuropathological data, reaches a clinical consensus diagnosis using published criteria, including proposed
clinical research criteria for CTE.
Results: We will investigate the validity of these clinical criteria and sources of error by using recently validated
neuropathological criteria as a gold standard for CTE diagnosis. We also will use statistical modeling to identify
diagnostic features that best predict CTE pathology.
Conclusions: The UNITE study is a novel and methodologically rigorous means of assessing clinicopathological
correlation in CTE. Our findings will be critical for developing future iterations of CTE clinical diagnostic criteria.
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Introduction
Chronic traumatic encephalopathy (CTE) is a progres-
sive neurodegenerative disease associated with repetitive
head impacts (RHI) [1–6]. Currently, CTE can be diag-
nosed only pathologically, although clinical research cri-
teria have been proposed [5, 7, 8]. The symptoms of
CTE, originally known as “punch drunk” or “dementia
pugilistica,” were first described in 1928 in boxers [9].
Pathological evidence of CTE has been observed only in
individuals with a history of head impacts that usually
were repetitive. Examples of these impacts include those
sustained during participation in contact sports, such as
American football, soccer, rugby, ice hockey, and pro-
fessional wrestling [2, 4, 10–14]; blast injuries sus-
tained by military service members [3, 12, 15]; poorly
controlled epilepsy; head-banging behaviors; and phys-
ical abuse [3, 16, 17].
The pathology of CTE is distinctive and clearly differ-
entiated from other neurodegenerative diseases, such as
Alzheimer’s disease (AD) and frontotemporal lobar de-
generation (FTLD) [10–12, 17–23]. Gross features of
CTE pathology include atrophy of the cerebral cortex
(especially the frontal and temporal lobes), diencephalon
and mammillary bodies, and cavum septum pellucidum
or septal fenestrations [2, 3, 12, 18].
Microscopically, CTE is characterized by the depos-
ition of hyperphosphorylated tau (p-tau) as neurofib-
rillary tangles, astrocytic inclusions, and neurites
irregularly distributed around small blood vessels,
preferentially at the depths of cerebral sulci [1–3, 24, 25].
In well-established disease, the tau pathology is most
prominent in the frontal and temporal lobes, hippocam-
pus, amygdala, and entorhinal cortex [12, 19, 20].
Symptom onset in CTE usually does not immediately
follow RHI, although the length of delay varies widely
[2, 3, 12, 19]. A constellation of cognitive, mood, and
behavioral symptoms, including impulsivity, aggression,
depression, apathy, suicidal ideation, episodic memory
loss, and executive dysfunction, have been described
[1–5, 12, 26]. Some individuals develop dementia as the
disease progresses in severity. Motor symptoms, including
gait instability, bradykinesia, and rigidity, are also com-
mon, usually late in the disease course [1, 3–5, 12, 26].
To date, understanding of the clinical presentation of
CTE has come largely from clinicopathological case
studies of individuals exposed to RHI based on clinical
interviews with family members after the individuals’
death [4, 26]. Owing to the recall bias inherent to retro-
spective studies and the ascertainment bias associated
with brain donation, there is a clear need for long-term,
prospective, longitudinal studies. However, those studies
will require a time period of nearly a decade or more be-
fore sufficient data can be generated to draw conclu-
sions. As those longitudinal studies are developed, it is
important to establish and refine consensus criteria for
clinical and pathological CTE diagnosis and to continue
gathering retrospective data to inform the long-term
prospective studies. The imperative to continue analyz-
ing clinical course and pathological correlates of CTE
using cost-effective, efficient, and immediately feasible
retrospective study designs is especially critical, given
the potential long-term health risks of RHI.
Understanding Neurologic Injury and Traumatic
Encephalopathy (UNITE) is a recently funded National
Institutes of Health (NIH) U01 project in which re-
searchers are examining the neuropathology and clinical
symptoms of brain donors who have experienced RHI.
The aim of the project is to study the relationship be-
tween clinical symptoms and the neuropathology of
CTE.
Here, we present the methodology of the UNITE study
for examining clinicopathological correlation. Specific-
ally, we set forth the following aims: (1) to investigate
the validity of recently proposed clinical criteria for CTE
[5] using a clinical consensus meeting and recently
validated neuropathological criteria for CTE ([2, 27],
(A.C. McKee) as a gold standard for CTE diagnosis; (2)
to identify sources of error between clinical consensus
diagnosis and the neuropathological diagnosis of CTE;
and (3) to identify individual diagnostic features that col-
lectively best predict CTE pathology.
Methods
The institutional review board at the Boston University
(BU) Medical Campus approved all of our research ac-
tivities (IRB number 31614). Because all participants are
deceased, consent does not need to be obtained. Figure 1
shows an overall flowchart of the study methodology.
The presented methodology resulted from several itera-
tions of updates based on investigator feedback.
Study recruitment
The U.S. Department of Veterans Affairs (VA)-BU-
Concussion Legacy Foundation (CLF) Brain Donation
Registry and Brain Bank is a collaborative effort of
the CTE Research Program within the BU Alzheimer’s
Disease Center (ADC), the VA Boston Healthcare System,
and CLF, a non-profit organization dedicated to brain
trauma research and education. Subject recruitment is on-
going and will occur throughout the 4-year study period.
Figure 2 shows recruitment mechanisms in place since
UNITE recruitment began in January 2014. For the major-
ity of the brain donors, the subjects’ next of kin contact
the brain bank and agree to donate near the time of death.
While living, some study subjects agree, through the Brain
Donation Registry, to donate their brain and spinal cord
after death. Potential subjects can register at any time,
provided they meet specific inclusion and exclusion
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criteria (detailed below). The registry currently has nearly
600 potential living subjects. We anticipate that several
hundred more will join the registry over the 4-year study
period. On the basis of the rate of brain donation in recent
previous work, we anticipate that 300 subject specimens
will be donated over the 4-year study period, with 20 % ac-
quired through the registry.
Eligibility criteria
Regardless of recruitment mechanism, potential subjects
are evaluated using the same inclusion and exclusion cri-
teria (Table 1). The inclusion criteria are based solely on
RHI exposure history, regardless of whether symptoms
are present. The criteria allow for breadth of RHI expos-
ure (e.g., athletics, military service, abuse) while requir-
ing sufficient intensity such that there is a reasonable
chance for the development of CTE (based on our ex-
perience, acknowledging that the relationship between
RHI and CTE is still under investigation). The inclusion
criteria are broader for women, who historically have
been investigated less thoroughly than men, and for in-
dividuals with amyotrophic lateral sclerosis (ALS), a par-
ticular research focus at our center. The exclusion
criteria prevent inclusion of brain and spinal cord speci-
mens of poor quality.
Consent
Consent for donation of brains and spinal cords is ac-
quired from the decedent’s legal next of kin or legally
authorized representative (LAR). The next of kin or
LAR also may consent for the donation of cerebrospinal
fluid (CSF), blood, and/or eye tissue for use in related
studies.
Brain acquisition
A member of the research team coordinates the extrac-
tion and shipment of the specimen. A properly trained
individual (pathologist, medical examiner, autopsy tech-
nician, diener) extracts the tissue locally. If immediate
shipment is possible, the specimen is placed on wet ice
and shipped using a courier service to minimize the
postmortem interval. If immediate shipment is not pos-
sible, the specimen is placed in 10 % formalin for fix-
ation for a minimum of 2 weeks before shipment.
Pathological processing and evaluation
The detailed methodology used for pathological pro-
cessing and evaluation has been published previously
[28, 29]. The McKee Laboratory evaluates brains ob-
tained from several brain banks, including -Concussion
Legacy Foundation, the Boston University-Alzheimer's
Disease Center, the Framingham Heart Study, the New
England Centenarian Study, the National Registry of Vet-
erans with Amyotrophic Lateral Sclerosis, and the Vet-
erans Administration National Posttraumatic Stress
Disorder Brain Banks. Regardless of individuals’ brain
bank membership, all brains are processed identically and
assigned a random identification number that does not
identify the brain bank to which they belong. Briefly, for
fresh tissue, quality control measures are followed, includ-
ing RNA integrity number (Agilent Technologies, Santa
Clara, CA, USA) and pH. The brain is hemisected, then
one half is sectioned and frozen and the other half is fixed
for 3 weeks. The fixed tissue is dissected and processed
into tissue sections, including paraffin-embedded tissue
sections and large, fixed coronal slabs. Tissue blocks
and stains are detailed in Table 2. If screening regions
are positive for β-amyloid, α-synuclein, or phosphory-
lated transactive response DNA binding protein 43 kDa
(pTDP-43), additional regions are stained to allow for
complete staging of these pathologies. Positive and
Fig. 1 Overall flowchart of the study methodology
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negative controls are stained simultaneously to identify
improperly stained material.
The pathological evaluation and diagnosis occur without
any knowledge of the subject’s RHI or clinical history and
are confirmed by two neuropathologists (ACM, TDS).
Semiquantitative measures of phosphorylated tau burden
(by AT8 immunostaining), β-amyloid deposition (by 4G8
immunostaining for Thal phase and Bielschowsky sil-
ver stain for Consortium to Establish a Registry for
Alzheimer’s Disease score), α-synuclein–positive Lewy
body and neurite burden, pTDP-43 burden, vascular
disease, and neuronal loss are recorded for prespecified re-
gions. The validated criteria for diagnosis ([2, 27], A.C.
McKee) and stages [2] of CTE are summarized in Tables 3
and 4. Well-established pathological criteria are used for
diagnosis of all comorbid diseases, including ALS [30, 31],
AD [32–37], Parkinson’s disease and Lewy body dis-
ease [38–40], FTLD (including progressive supra-
nuclear palsy, corticobasal degeneration, and Pick’s
disease) [41–45], and multiple system atrophy [43]. A
neuropathology report is generated that includes a de-
scription of the macroscopic and microscopic findings
and a list of pathological diagnoses, including CTE
stage.
Retrospective clinical evaluation
The goal of the retrospective clinical evaluation is to
obtain each subject’s demographic information; RHI ex-
posure; substance use; and medical, social, and family
Fig. 2 Recruitment mechanisms in place at the U.S. Department of Veterans Affairs–Boston University–Concussion Legacy Foundation
Brain Donation Registry and Brain Bank since Understanding Neurologic Injury and Traumatic Encephalopathy project recruitment
began. Next-of-kin recruitment: A potential donor’s legal next of kin contacts the brain bank near the time of death to ask about
participation. Active recruitment: A member of the brain bank staff contacts a potential donor’s next of kin near the time of death to
ask about participation. Brain Donation Registry: A potential donor contacts the brain bank and pledges to donate upon death. Medical
examiner: A medical examiner contacts the brain bank upon suspicion of a diagnosis of chronic traumatic encephalopathy or if an
individual’s family member expresses to the medical examiner interest in brain donation. Consultations: A neuropathologist contacts the
brain bank to release tissue for further evaluation
Table 1 Inclusion and exclusion criteria for the UNITE study
Descriptions
Inclusion criteria
1. Men who played American football or ice hockey at the professional
or Olympic level or who played at the collegiate, semiprofessional, or
junior level for at least 2 years
2. Men who played a high-risk contact sport, other than American
football or ice hockey, at the professional or Olympic level
3. Women who played a high-risk contact sport at the professional,
Olympic, or collegiate level
4. Men or women who played a high-risk contact sport at the
professional, Olympic, collegiate, or high school level who died
before the age of 35 years
5. Men or women who played a high-risk contact sport at the
professional, Olympic, collegiate, or high school level who were
diagnosed with ALS during life
6. Men or women with a military history of combat exposure
7. Women with a history of domestic abuse
Exclusion criteria
1. Specimen with a postmortem interval before fixation of longer than
72 h
2. Specimen that was embalmed following brain autopsy
3. Specimen of less than one full hemisphere
ALS, Amyotrophic lateral sclerosis; UNITE, Understanding Neurologic Injury and
Traumatic Encephalopathy
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histories, with a particular focus on possible neurode-
generative conditions, including symptom breadth,
severity, and progression. The retrospective clinical
evaluation comprises a combination of online surveys
and telephone calls between researchers and the family
members and close friends of the subject. Data are col-
lected through an unstructured interview with either a
behavioral neurologist or a neuropsychologist and with
modified (for completion retrospectively, following
death, by informants) versions of standardized, validated
scales (Table 5). Preference was given to scales already in
use in other relevant BU studies, including studies of
CTE and AD [46–49], and to scales that are included in
the National Institute of Neurological Disorders and












Olfactory bulb 1 X X X X
Midbrain at level of red nucleus 1 X X X X X
Midbrain at superior cerebellar peduncle 1 X
Precentral, postcentral cortices (BA 4, 3, 2, 1) 1 X X
Inferior parietal cortex (BA 39, 40) 1 X X X X X
Anterior cingulate (BA 24) 1 X X
Superior frontal (BA 8, 9) 1 X X X
Inferior frontal cortex (BA 10, 11, 12) 2 X X X
Dorsolateral frontal (BA 45, 46) 2 X X X X X X
Caudate-putamen-accumbens, septal cortex 2 X X X
Insular cortex 2 X X
Temporal pole (BA 38) 1 X X X
Superior temporal (BA 20, 21, 22) 1 X X X X
Amygdala, with entorhinal cortex (BA 28) 1 X X X X X X
Globus pallidus, insula, substantia innominata 1 X X
Anterior hippocampus 1 X
Hippocampal formation, lateral geniculate 1 X X X X X X
Superior temporal posterior (BA 41, 42) 1 X
Thalamus with subthalamic nucleus 1 X
Hypothalamus, mammillary body 1 X X
Posterior thalamus 1 X
Posterior cingulate (BA 23, 31) 1 X
Calcarine cortex (BA 17, 18) 1 X X X
Superior parietal cortex (BA 7B) 1 X
Upper pons (level of locus coeruleus) 1 X X X
Pons, middle cerebellar peduncle 1 X
Medulla oblongata with inferior olives 1 X X X X
Cervical spinal cord 1 X X X
Thoracic spinal cord 1 X
Lumbar spinal cord 1 X
Sacral spinal cord 1 X
Cerebellar vermis 1 X X
Cerebellum with dentate nucleus 1 X X X X X
Parastriate cortex 1 X
Abbreviations: BA Brodmann area, pTDP-43 phosphorylated transactive response DNA binding protein 43 kDa
aIf screening regions are positive for β-amyloid, α-synuclein, or pTDP-43, additional regions are stained to allow for complete staging of these pathologies
bMinimum regions that must be evaluated to make a neuropathological chronic traumatic encephalopathy diagnosis
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Stroke (NINDS) Common Data Elements. Researchers
conducting these evaluations are completely blinded to
the pathological examinations and findings.
There are five parts to the clinical evaluation: two on-
line surveys (termed Online Surveys A and B), two tele-
phone interviews (termed Clinical Interviews A and B),
and a medical record review. Informants may complete
the online surveys individually or as a group (i.e., several
members of the decedent’s family responding together).
For the clinical interviews, informants participate as a
group. A behavioral neurologist or neuropsychologist
(termed the lead clinician) conducts Clinical Interview A,
and a research assistant conducts Clinical Interview B. To
assess informant reliability, informants answer questions
pertaining to the nature and duration of their relationship
with the subject and the frequency with which they were
in contact with the subject. A description of each part of
the clinical evaluation (presented in the order in which
the data are collected) is provided in the subsections
below.
Online Survey A
Online Survey A queries the subject’s demographic in-
formation, educational attainment, occupational history,
living situation before death, athletic history (type of
sports played, level, position, age of first exposure, and
duration), and military history (branch, location of ser-
vice, and duration of combat exposure). The survey uses
a nested question structure with skip logic to ensure that
questions are appropriately tailored to each subject.
Clinical Interview A
During Clinical Interview A, the clinician (a behavioral
neurologist or a neuropsychologist) obtains a detailed
medical history, including traumatic brain injuries (TBIs),
and recreates a timeline of cognitive, behavioral, and
mood symptomatology. Specifically, the clinician asks
semistructured questions about cause of death, medical
history (including vascular risk factors), neurological his-
tory (including risk factors for cognitive and motor im-
pairment), and psychiatric history. The clinician then asks
semistructured questions about mild to severe TBIs using
the Ohio State University TBI Identification Method Short
Form [50] and two questionnaires, adapted from pub-
lished studies, that address military-related head injuries
and concussions that result in even the mildest symptoms
[47, 48]. Finally, using unstructured questions, the clin-
ician obtains a precise chronology of deficits in cognition
(memory, executive function, attention/concentration,
language, visuospatial function), behavior and/or mood
(depression, apathy, mania, anxiety, irritability/anger, abu-
siveness, social inappropriateness, psychosis), and daily
function (including instrumental activities of daily living).
Table 3 Pathological criteria used for CTE diagnosis
Descriptions
Defining criteria
1. Perivascular accumulation of abnormal hyperphosphorylated tau
within neurons, astrocytes, and/or cell processes in the neocortex
2. Irregular distribution of p-tau–immunoreactive cells and processes
at the depths of cerebral sulci
Supportive criteria
3. Macroscopic abnormalities in the septum pellucidum (cavum,
fenestration), disproportionate dilation of the third ventricle or
signs of previous brain injury
4. Abnormal tau-immunoreactive neuronal lesions affecting the
neocortex predominantly in superficial layers 2 and 3, as opposed
to layers 3 and 5 as in AD
Abbreviations: AD Alzheimer’s disease, CTE chronic traumatic encephalopathy
These criteria are based on previous publications [2, 27] and A.C. McKee
Table 4 CTE pathological stages
Stages Descriptions
1 Discrete perivascular p-tau foci in the neocortex, usually found
at the depths of sulci
2 Multiple perivascular p-tau foci in the neocortex, typically at the
depths of the cerebral sulci, with involvement of superficial
layers of adjacent cortex and sparing of the medial temporal
lobe structures
3 Widespread p-tau lesions in the frontal, temporal, parietal,
insular, and septal neocortices, most severe at the depths of
the sulci and in the superficial cortical layers, with involvement
of the entorhinal cortex, amygdala, and hippocampus
4 Diffuse pathology throughout the cerebral cortex and the
medial temporal structures, sparing the calcarine cortex
Abbreviation: CTE chronic traumatic encephalopathy, p-tau phosphorylated tau
CTE pathological stages are based on extent and anatomic distribution of
p-tau pathology [2]
Table 5 Administered clinical scales
Scales Clinical evaluation
sections
Ohio State University TBI Identification Method
Short Form [50]
Clinical Interview A
Geriatric Depression Scale [51] Online Survey B
Cognitive Difficulties Scale [52]
Behavioral Rating Inventory of Executive
Function–Adult Version [53]
BIS-11 [54]
Apathy Evaluation Scale [55]
ALS Functional Rating Scalea [56]
Functional Assessment Questionnaire [57] Clinical Interview B
Clinician Assessment of Fluctuations [58]
Brown-Goodwin Aggression Scale [59]
Structured Clinical Interview for DSM-IV [60]
Abbreviations: ALS Amyotrophic lateral sclerosis; DSM-IV Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition, TBI Traumatic brain injury
All scales were adapted to account for data being collected retrospectively
from an informant
aAdministered only for subjects diagnosed with ALS during life
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Motor functioning, sleep, headaches, substance use, and
family history are queried in the same manner. Once the
interview is completed, the clinician answers several sum-
mary questions about predominant symptoms (cognitive,
mood, behavior, motor), symptom onset, and disease
progression.
Online Survey B
Online Survey B is used to collect data about the
subject’s cognition, mood, and behavior (including im-
pulsivity and apathy) through the administration of the
following validated scales: Geriatric Depression Scale
Short Form [51], Cognitive Difficulties Scale (CDS) [52],
Behavior Rating Inventory of Executive Function–Adult
Version [53], Barratt Impulsivity Scale version 11 (BIS-11)
[54], and Apathy Evaluation Scale (AES) [55]. For subjects
diagnosed during life with ALS, the ALS Functional
Rating Scale [56] is also administered.
Clinical Interview B
In Clinical Interview B, the researcher asks informants
semistructured questions to quantify information obtained
qualitatively in Clinical Interview A. Some questions from
Online Survey B are repeated for quality control. Specific-
ally, family history is obtained using modified questions
from the National Alzheimer’s Coordinating Center
Uniform Data Set [49]. Cognitive functioning, including
memory, language, attention, executive function, and
visuospatial function, is assessed using selected questions
from the informant section of the CDS [52]. Daily func-
tion, cognitive fluctuations, and aggression are assessed
using the Functional Assessment Questionnaire [57], the
Clinician Assessment of Fluctuations [58], and the Brown-
Goodwin Aggression Scale [59], respectively. Impulsivity
and apathy are assessed using selected questions from the
BIS-11 [54] and the AES [55], respectively. The presence
of major depressive disorder, bipolar disorder, anxiety
disorders (including panic disorder, obsessive compulsive
disorder, agoraphobia, social anxiety disorder, specific
phobias, generalized anxiety disorder, and posttraumatic
stress disorder), psychosis, substance use, and somatoform
disorders is assessed using modified questions from the
Structured Clinical Interview for DSM-IV [60]. Sleep and
headache are briefly assessed using modified questions
from the Mayo Sleep Questionnaire [61] and the
Cleveland Clinic Headache Intake Questionnaire, respect-
ively [62]. Motor function is assessed using questions de-
veloped internally to query symptoms of parkinsonism.
Medical record review
For all incoming cases, we request permission from the
subject’s legal next of kin or LAR to review medical
records as well as the names and locations of health care
providers. A research assistant contacts the health care
providers to request the records, including original brain
imaging (rather than just a report). The research assist-
ant initially reviews all records and extracts salient
information, including psychiatric, neurological, and
neuropsychological evaluations; brain imaging; medical
history; and medications. A behavioral neurologist and a
neuropsychologist then review the extracted informa-
tion, including original images if available. Information
gathered during the medical record review is combined
with the data gathered in the previous steps to complete
the clinical evaluation.
Clinicopathological consensus conference
Clinical consensus methodology is based on recommen-
dations of Bertens et al. [63]. At a twice-monthly clinico-
pathological consensus conference (CPC), a panel of
doctoral-level clinicians reaches a clinical consensus
diagnosis using clinical research criteria [38, 61, 64–69],
including those recently proposed for CTE [5] (Fig. 3).
The clinical panel is composed of neuropsychologists,
neurologists, psychiatrists, and neurosurgeons who
specialize in neurodegenerative disease and/or TBI. At
least three and upward of six panel members are present
for each CPC.
For each case, a lead clinician reads a standardized
clinical summary based on the information collected
during the retrospective clinical evaluation. This sum-
mary outlines the disease course. It also includes age at
death and cause of death; a subjective assessment of
informant reliability; prior athletic, military, and TBI his-
tory; past medical, educational, and occupational history;
living situation before death; substance use history; and
family history. Last, it includes salient features in med-
ical records, including neuropsychological testing, neu-
roimaging (including a reading from a behavioral
neurologist if original images are available), CSF bio-
markers, diagnoses made during life, and medications
prescribed. At the conclusion of the clinical presentation
and before any formal discussion, each clinical consen-
sus member votes independently, without discussion, on
whether criteria for traumatic encephalopathy syndrome
(TES) [5] are met. The diagnosis of TES, which incor-
porates CTE, is made on the basis of criteria outlined
by Montenigro et al. [5], with modification because
neuropsychological testing may not have been con-
ducted during the subject’s life. Although several
groups have proposed CTE clinical criteria [7, 8], use
of the Montenigro et al. criteria provides several ad-
vantages. To be included in the core criteria, signs
and symptoms needed to be frequent (70 %) among
cases diagnosed neuropathologically with CTE using
the criteria proposed by McKee et al. [2] and free of
comorbid neurodegenerative disease. The criteria also
are operationalized for research, explicitly defining the
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minimum required exposure level, supportive features,
subtype designations, potential biomarkers, and rela-
tive likelihood of CTE (probable, possible, or un-
likely). Of note, TES is a broad umbrella term meant
to describe the clinical presentation of CTE as well as
other possible long-term consequences of RHI,
including other neurodegenerative diseases. A TES
diagnosis neither necessitates a possible or probable
CTE diagnosis nor excludes another clinical neurode-
generative diagnosis [5].
If the criteria for TES are met, the clinician indicates
the subtype designations and the relative likelihood of
Fig. 3 Adapted clinical diagnostic criteria for traumatic encephalopathy syndromea. Abbreviations: CSF cerebrospinal fluid, CTE chronic traumatic
encephalopathy, PET positron emission tomography, p-tau phosphorylated tau, RHI repetitive head injuries, TBI traumatic brain injury, TES
traumatic encephalopathy syndrome. aCriteria adapted from Montenigro et al. [5]
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underlying CTE (probable, possible, or unlikely) based
upon additional supportive features [5]. The clinicians
also record a primary clinical diagnosis and, if appropri-
ate, contributing clinical diagnoses. Figure 4 shows the
diagnostic form that each clinician completes. After each
clinician, blinded to the other clinicians’ diagnoses, com-
pletes and submits the diagnostic form, the group dis-
cusses the case. The discussion includes questioning of
the lead clinician about specific details with the goal of
reaching a consensus diagnosis using a format identical
to that used for the previous independent voting. To
reach consensus, a majority of the clinicians present
must agree on the diagnosis. Once a consensus diagnosis
is reached, panel members again complete a written
diagnostic form as a means to record dissent from the
consensus.
After the clinicians reach a consensus, the neuropath-
ologist who evaluated the case presents the pathological
findings. The presentation includes the brain weight,
gross and microscopic images, and an overall summary.
The presentation focuses on 1) regional patterns of cere-
bral and white matter atrophy, 2) evidence of septal ab-
normalities, including cavum septum pellucidum or
fenestrations, 3) pallor of the substantia nigra and locus
coeruleus, 4) extent and anatomic distribution of neur-
onal loss and gliosis, 5) immunohistochemistry (p-tau,
β-amyloid, pTDP-43 and α-synuclein) and 6) vascular
pathology. The summary includes pathological diagnoses
with staging when appropriate. All neuropathological
diagnoses and associated reports are completed before
the consensus conference and without knowledge of the
subject’s antemortem exposure history or clinical presen-
tation, and they are not changed on the basis of clini-
cians’ diagnoses or discussions.
After the clinical and pathological presentations, the
clinicians and pathologists discuss clinicopathological
correlation. For each case, the physicians and neuropsy-
chologists identify key summary features of the case that
help inform future research directions. For cases with
discrepancies between the clinical and pathological find-
ings, the cause of the differences and how the discrepan-
cies contribute to diagnostic uncertainty are discussed.
Last, the lead clinician and pathologist present both
the clinical and pathological diagnoses to the informants
by telephone. The informants are also provided with a
written report that summarizes the diagnoses.
Fig. 4 Clinical consensus diagnostic form completed by each clinician. ALS amyotrophic lateral sclerosis, CNS central nervous system, CTE chronic
traumatic encephalopathy, FTD frontotemporal degeneration, TBI traumatic brain injury, TES traumatic encephalopathy syndrome
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Data analysis
The data analysis will involve three major phases. Phase
1 will evaluate the reliability of the consensus raters and
the validity of the clinical research criteria for CTE and
the consensus process [63, 70]. For our primary analyses,
we will consider a dichotomous clinical diagnosis (i.e.,
possible or probable CTE vs. no CTE). First, we will
calculate the pre- and postconsensus interrater reli-
ability (Cohen’s κ) between clinical consensus mem-
bers [63, 70, 71], along with the standard errors and
95 % confidence intervals. Next, we will calculate the
pre- and postconsensus sensitivity, specificity, and ac-
curacy of the clinical diagnosis using the presence of
CTE pathology as a gold standard. In secondary ana-
lyses, we will assess the reliability and validity of clin-
ical subtypes and an alternative operationalization of
the likelihood of CTE (i.e., probable CTE vs. possible
or no CTE).
Phase 2 of the analysis involves an evaluation of
sources of diagnostic disagreement between clinical con-
sensus members and sources of diagnostic error between
the consensus diagnosis and the pathological diagnosis.
For each case with diagnostic disagreement (either pre-
or postconsensus), we will review the case and identify
the issues leading to the disagreement. We will review
how these major issues differ pre- and postconsensus,
paying particular attention to those that remain or that
occur postconsensus. Similarly, for each case with a con-
sensus diagnostic error, we will review the case and
identify the major issue leading to the error. We will cal-
culate the frequency of each type of diagnostic error
(e.g., frequency of clinical consensus diagnosis of CTE
with pathological AD). Finally, we will review differences
in diagnostic errors between false positives and false
negatives.
Phase 3 involves the analysis of individual diagnostic
features (examples include but are not limited to contact
sport position, years and level of play, number and se-
verity of individual TBIs, memory impairment, depres-
sion, impulsivity, and motor impairment). We will
calculate the sensitivity and specificity of each feature
using pathological CTE as a gold standard. Among cases
of pathological CTE, we will calculate the frequency of
each feature overall, as the presenting symptom and/or
sign, as an early symptom and/or sign, and as a late
symptom and/or sign. Next, we will create statistical
models of pathological CTE risk, using these diagnostic
features as predictors. We will use conventional logistic
regression as well as two machine learning algorithms:
random forests and elastic net penalized logistic regres-
sion. The machine learning algorithms account for the
often erroneous assumptions of classical logistic regres-
sion that predictors are not correlated with each other
and that their effects are additive [72]. Diagnostic
features with the best sensitivity and specificity, and that
best predict CTE pathology, will be critical to include in
future iterations of clinical diagnostic criteria for CTE.
Discussion
The last decade has seen an increased interest in under-
standing the relationship between RHI and the develop-
ment of neurodegenerative disorders, most centrally
CTE. As CTE is closely linked to participation in contact
sports such as American football and to head injuries
sustained by soldiers participating in the conflicts in Iraq
and Afghanistan, the topic also has garnered consider-
able attention from the media and the public at large.
Recently, the NIH, the National Football League (NFL),
and the U.S. Department of Defense sponsored further
research to elucidate the connection between RHI and
the development of CTE [73–75]. The UNITE study is
part of this initiative. Here, we describe the UNITE
study methodology for examining clinicopathological
correlation in CTE.
The UNITE methodology has several strengths, in-
cluding extensive and carefully designed data collection
and the use of best practices to reach a clinical consen-
sus diagnosis [63]. Retrospective clinical data collection
from informants includes an unstructured interview, a
structured interview, two online surveys, and a review of
medical records. In the unstructured interview, an expe-
rienced behavioral neurologist or neuropsychologist ob-
tains a comprehensive disease timeline, similarly to an
initial clinical visit, so that the case can be presented in
detail at a consensus conference. Via the structured
interview and online surveys, data are collected that can
be coded and analyzed to answer questions about signs
and symptoms of disease, independently of the consen-
sus diagnosis. Pathological data collection includes ex-
haustive sampling of brain regions and comprehensive
immunohistochemical analysis. All vascular and neuro-
degenerative pathological diagnoses are made on the
basis of recently validated CTE criteria ([2, 27], A.C.
McKee) or other well-established criteria.
In designing our methodology for reaching a clinical
consensus diagnosis, we followed best practices, paying
careful attention to the evaluating panel’s constitution,
information presented to the panel, and the diagnostic
decision-making process for consensus [63, 76]. Our
panelists have diverse training (behavioral neurology,
neurosurgery, neuropsychology, brain injury and re-
habilitation, and psychiatry) and decades of professional
experience in areas germane to the study of CTE, in-
cluding neurodegenerative disease and TBI. The infor-
mation presented to the panel is based on methodology
used in the study of AD [77] and consists of a written
summary of the disease course and medical, social, and
family histories [1, 5, 7, 26]. The diagnostic decision-
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making process follows recommended procedures.
Consensus members make an individual preliminary
diagnosis before discussion with other panel members.
Consensus diagnosis, subtype designations, and likeli-
hood of CTE are determined by majority vote after a
panel discussion. Individual dissension from the consen-
sus diagnosis is recorded for later analysis [63].
Our study design allows not only for testing the valid-
ity of clinical research criteria and the consensus process
but also for recognizing sources of error and identifying
diagnostic features that best predict CTE pathology. We
have proposed several approaches in the Data Analysis
section above to conduct these analyses that will allow
us to move past the traditional case series approach that
has largely defined CTE research to date. For example,
whereas there are clear pathological differences between
CTE and AD, understanding and differentiating the clin-
ical symptoms, particularly in older adults, remains a
significant challenge [78]. Analyzing the cases collect-
ively using a quantitative approach will help us better
understand the clinical distinctions between these dis-
eases. Clinical diagnostic features that best predict CTE
pathology will be critical to include in future iterations
of clinical diagnostic criteria for TES and CTE. In particu-
lar, as potential in vivo biomarkers for CTE are developed,
the UNITE methodology will provide a critical mechanism
by which to examine their predictive validity.
We strive to be methodologically rigorous, but several
potential limitations need to be highlighted. In any study
involving brain donation, there is clear ascertainment
bias. Even though brain donors are selected on the basis
of their exposure to repetitive brain trauma, families that
donate are more likely to have witnessed symptoms dur-
ing the donor’s life [26]. Ascertainment bias increases
the probability of CTE being present at autopsy and may
also limit variability and increase the mean severity of
clinical presentation. All of these factors in turn could
affect the reliability and validity of the consensus diagno-
sis. To address this bias, our recruitment network ac-
tively encourages the recruitment of subjects without or
with limited symptoms who were exposed to RHI. As
more asymptomatic brain donors are included in the
study, the generalizability of our findings will increase.
Because we ask informants to recall information from
years earlier, there is potential for recall bias. Informants
may recall events or symptoms more clearly if they oc-
curred closer to the time of death or if they strongly af-
fected the informant. Further, if the informants did not
witness events, they may be unaware or poorly informed
of what occurred. This is especially common for sub-
jects’ children who may not have been living or who
were very young when RHI occurred. We have tried to
reduce recall bias by making our structured interview
comprehensive so that informants must only recognize
that symptoms were present rather than need to freely
recall that they occurred. We also pay special attention
to the age at individual symptom onset.
Because we do not evaluate subjects during their lives,
the lead clinician cannot present firsthand observations
of the subject and standardized, objective data, including
neuropsychological and biomarker data, cannot be col-
lected. The lack of these data introduces error into the
clinical diagnoses. Although we carefully review medical
records, including clinicians’ impressions and neuro-
psychological, imaging, and CSF data, the medical rec-
ord data we collect are neither universal nor uniform.
Further, there may be discrepancies between the data
collected from informants and medical record data.
Because the structured data collection is standardized
and these data are present for all subjects, we plan to
use these data alone for our item-level analyses. How-
ever, for the consensus diagnosis, we consider all
data—structured, unstructured, and from the medical
record review. It is up to the lead clinician to present
a cogent history to the consensus group, acknowledg-
ing to the group any discrepancies in the data.
Clinicopathological studies are not designed to assess
causality. To assess whether trauma is a cause of CTE in
a human study would require precise longitudinal
monitoring of brain trauma exposure and a method to
detect and monitor the presence of CTE during life,
neither of which is currently possible. Numerous case
reports and case studies have strongly suggested a dir-
ect association between RHI and the development
CTE [2, 10–12, 15, 26, 79], and all cases of pathologic-
ally confirmed CTE have included a history of RHI.
The goal of the UNITE study is not to establish this
causal link, but rather to examine clinicopathological
correlation. However, given the strong association be-
tween RHI and CTE, RHI is a central component of
the UNITE inclusion criteria.
Finally, the retrospective clinicopathological approach
has been used successfully to characterize neurodegener-
ative disease over the past century [74, 75]. In AD, the
development of clinical diagnostic criteria [64] and the
retrospective validation of these criteria using consensus
diagnosis and neuropathology as a gold standard [77]
long preceded prospective longitudinal validation. Simi-
lar retrospective methodology also was used for other
neurodegenerative diseases, including the behavioral
variant of frontotemporal dementia [61].
Conclusions
In the 20 months of active study recruitment to date,
our team has successfully brought 99 cases to consensus
and an additional 28 brain donations are awaiting con-
sensus evaluation. When combined with previous cases,
the VA-BU-CLF brain bank currently holds 172
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pathologically confirmed cases of CTE, representing the
vast majority of cases of CTE reported to date [80]. This
collection of CTE cases has already led to important
advances in understanding of the pathobiology of CTE
[2, 12, 21, 81] and has been instrumental in the initial
stages of validation of the neuropathological criteria for
CTE [2]. Although beyond the scope of this article,
UNITE has several additional goals, including imaging
of ex vivo tissue to guide the development of CTE
biomarkers, investigating neurodegenerative comorbidity
in CTE, staging of CTE disease severity, modeling RHI
as risk factor for CTE, and evaluating genes and
gene–environment interactions as a risk factor for
CTE. In coordination with NIH biobanks and the
Federal Interagency Traumatic Brain Injury Research
informatics system, the VA-BU-CLF brain bank and
the UNITE study will be used to establish a multisite
biospecimen and data repository that will make tissue
and data available to qualified investigators around
the world who are studying the effects of RHI. These
initiatives funded by NINDS and the National Institute of
Biomedical Imaging and Bioengineering also will be fun-
damental to understanding CTE pathogenesis, determin-
ing therapeutic research targets, and advancing the
clinical diagnosis of CTE.
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